HLNE vs LMND

HLNE exhibits exceptional fundamental health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.28. While the current price of $92.28 trades at a premium to its Graham Number ($49.52) and Intrinsic Value ($71.80), it remains significantly undervalued relative to its analyst target of $155.14 and sector average P/E. The stock is currently experiencing a severe technical correction, trading near its 52-week low, which creates a compelling entry point for a company with 31.7% ROE and consistent earnings beats. The divergence between deteriorating price action and strengthening financial health suggests a high-probability reversal.

Lemonade exhibits critical financial weakness with a Piotroski F-Score of 1/9, indicating severe instability in fundamental health. While the company demonstrates impressive top-line revenue growth of 53.5%, it remains deeply unprofitable with a negative ROE of -29.37% and a negative profit margin. Insider sentiment is strongly bearish, characterized by significant selling from the CEO and CFO with zero buying activity. The current valuation represents a massive premium over book value (P/B 9.36), making the stock a high-risk speculative play despite recent price momentum.